Imunon, Inc. (IMNN) has its full attention on the successful execution of the Phase 3 OVATION 3 trial, which is evaluating IMNN-001 in combination with standard-of-care neoadjuvant and adjuvant chemotherapy in women with newly diagnosed advanced ovarian cancer. The company recently announced a strategic restructuring to align its resources to rapidly advance the OVATION 3 trial, which includes the retirement of Chief Scientific Officer Dr. Khursheed Anwer and the redefining of job descriptions for additional employees to reduce operating expenses. Imunon is currently evaluating different funding options and in the near-term will likely employ one or two additional bridge financings like the recently completed $7.0 million registered direct offering as a means to ensure uninterrupted continuation of the OVATION 3 trial until long-term financing is secured.
